Pulmonologist Gregory C. Kane, MD, has received one of the highest academic honors bestowed on physicians: an endowed professorship.
Dr. Kane, who is also interim chair of the Department of Medicine, has been named the first Jane and Leonard Korman Professor of Pulmonary Medicine. An endowed professorship benefits patients, young doctors in advanced training, and our community by ensuring that a physician’s position and expertise in the field are funded in perpetuity.
Endowed professorships are “crucial to attracting and retaining the best faculty,” said Jefferson Medical College dean Mark Tykocinski, MD, at Dr. Kane’s investiture ceremony.
Dr. Kane is renowned in the field of pulmonary and critical care medicine. Clinically his patients appreciate the experience and knowledge that he brings to their care. Recently for example, Suzanne Berman turned to Dr. Kane when a persistent cough could not be explained by other specialists and got treatment after the physician’s diagnostic detective work identified the cause of her problem.
He has published more than 55 original articles and received numerous awards for his teaching abilities both at Jefferson and nationally. He is also a Jefferson “lifer.” A graduate of the Jefferson Medical College class of 1987, Dr. Kane has been at Jefferson throughout his medical career.
The Korman family has long supported Jefferson.
Last year, a major grant from the Jane and Leonard Korman Family Foundation helped establish the Jefferson – Jane and Leonard Korman Lung Center. The Center’s core missions are to develop a better understanding of lung diseases through innovative research as well as to improve patient care excellence.
Mr. Korman has been a University trustee since 1998.
With its primary focus on lung cancer, the cause of more than 160,000 deaths a year in the U.S., the Center will attack the leading cause of cancer death. Because lung cancer often progresses like a stealth disease, early diagnosis and improving treatment is of vital concern. It, as well as several pulmonary diseases, is a deeply personal and life-altering disease for patients and their families.
The Korman’s latest investment will ensure that Jefferson has the leadership and expertise it needs to create an excellent program for the treatment and prevention of lung cancer and lung diseases including cystic fibrosis, emphysema, pneumonia, and asthma for years to come.